Xeris Biopharma Holdings (XERS) Consolidated Net Income (2020 - 2026)

Xeris Biopharma Holdings has reported Consolidated Net Income for 7 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 124.23% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $12.0 million (up 126.64% YoY), and the FY2025 full-year result was $554000.0, up 101.01% from the prior year.
• Consolidated Net Income for Q1 2026 stood at $2.2 million, down from $11.1 million in the prior quarter.
• The five-year high for Consolidated Net Income was $11.1 million in Q4 2025, with the low at -$33.7 million in Q1 2022.
• Historically, Consolidated Net Income has averaged -$12.3 million across 5 years, with a median of -$13.4 million in 2023.
• Annual changes were most pronounced in 2022 — Consolidated Net Income slumped 83.12% — and 2025, when it surged 316.72%.
• Xeris Biopharma Holdings' Consolidated Net Income stood at -$12.9 million in 2022, then decreased by 3.56% to -$13.4 million in 2023, then soared by 61.81% to -$5.1 million in 2024, then surged by 316.72% to $11.1 million in 2025, then tumbled by 79.84% to $2.2 million in 2026.
• The last three Consolidated Net Income figures came in at $2.2 million (Q1 2026), $11.1 million (Q4 2025), and $621000.0 (Q3 2025), per Business Quant data.